Dealing with frequent hitters in drug discovery: a multidisciplinary view on the issue of filtering compounds on biological screenings. (2nd December 2019)

• Record Type: Journal Article
• Authors: Dantas, Rafael Ferreira; Evangelista, Tereza Cristina Santos; Neves, Bruno Junior; Senger, Mario Roberto; Andrade, Carolina Horta; Ferreira, Sabrina Baptista; Silva-Junior, Floriano Paes
• Is Part Of: Expert opinion on drug discovery. Volume 14:Number 12(2019)
• Page Start: 1269
• Page End: 1282
• Publication Date: 2019-12-02
• Subjects: Chemical biology -- cheminformatics -- multi-target -- PAINS -- polypharmacology -- privileged scaffolds; 615.1
• DOI: 10.1080/17460441.2019.1654453
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction : The timely identification biologically active chemicals, in disease relevant screening assays, is a major endeavor in drug discovery. The existence of frequent hitters (FHs) in non-related assays poses a formidable challenge in terms of whether to consider these molecules as chemical gold or promiscuous non-selective reactive trash (also known as PAINS – pan assay interference compounds). Areas covered : In this review, the authors bring together expertize in synthetic chemistry, cheminformatics and biochemistry, three key areas for dealing with FHs. They discuss synthetic methods facilitating preparation of chemically diverse molecular libraries, while favoring activity in the biological space. They also survey and discuss recent computational advances in the prediction of PAINS from chemical structures. Finally, they review experimental approaches for the validation of the biological activity of screening hits and discuss alternatives for exploiting promiscuity and chemical reactivity. Expert opinion : It's essential to develop more efficient computational methods to reliably recognize PAINS in distinct molecular environments. Accordingly, advances in synthetic chemistry hold the promise to provide a better quality of chemical matter for drug discovery. Medicinal chemists should be more open to screening for hits showing biologically complex mechanisms of action rather than discarding molecules that may prove valuable as innovative disease treatments.